Liposomal Annamycin (L-Annamycin)

DRUG2 trials

Sponsors

Moleculin Biotech, Inc., Maria Sklodowska-Curie National Research Institute of Oncology

Conditions

Pulmonary MetastasisSarcoma,Soft TissueSoft Tissue Sarcoma

Phase 1

Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases

CompletedNCT04887298

Moleculin Biotech, Inc.Pulmonary Metastasis, Sarcoma,Soft Tissue

Start: 2021-06-05End: 2024-08-06Updated: 2024-10-24

Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases

Maria Sklodowska-Curie National Research Institute of OncologyPulmonary Metastasis, Soft Tissue Sarcoma

Start: 2022-08-23End: 2025-08-31Target: 64Updated: 2022-08-26

Related Papers

Abstract LB180: Non-cardiotoxic properties of annamycin, a clinically evaluated anthracycline and potent topoisomerase 2β poison

Cancer Research2024-04-05

Abstract 4048: New approach to target metastatic colorectal cancer organotropism with L-Annamycin

Cancer Research2022-06-15

Abstract P218: Annamycin, a novel non-cardiotoxic anthracycline with high activity against sarcomas metastatic to lungs

Molecular Cancer Therapeutics2021-12-01